Massive 5,000-Patient study tracks brain side effects of new Alzheimer's drug
NCT ID NCT06322667
Summary
This study is monitoring the safety of lecanemab, a drug for early Alzheimer's disease, in real-world medical practice. It will follow 5,000 patients to track specific brain imaging side effects, including swelling and small bleeds, known as ARIA. The main goal is to see how often these side effects occur and how doctors manage treatment when they happen.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Eisai trial site 1
RECRUITINGTokyo, Japan
-
Eisai trial site 2
RECRUITINGHiroshima, Japan
-
Eisai trial site 3
RECRUITINGKyoto, Japan
Conditions
Explore the condition pages connected to this study.